CG Oncology director granted 9,354 stock options

CG Oncology, Inc. director Victor Edward Tong Jr. received a grant of stock options covering 9,354 shares of common stock.

Rhea-AI Filing Summary

CG Oncology, Inc. director Victor Edward Tong Jr. received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036.

These options vest in 12 equal monthly installments after June 4, 2026, the grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion vests on the meeting date, contingent on his continued service.

Insider Trade Summary

Grant/Award: 9,354 shares

Grant/Award 1 txn

Insider Tong Victor Edward Jr

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,354	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 9,354 contracts (Direct)

Footnotes (1)

1. F1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Stock options granted: 9,354 options Exercise price: $56.09 per share Expiration date: June 3, 2036 +2 more

5 metrics

Stock options granted 9,354 options Director stock option grant covering common stock

Exercise price $56.09 per share Strike price for the 9,354-share option grant

Expiration date June 3, 2036 Option term end date for director grant

Post-grant derivative holdings 9,354 options Total derivative securities following transaction

Vesting start date June 4, 2026 Monthly vesting of 1/12 of options begins after this date

Key Terms

Director Stock Option, exercise price, expiration date, vesting, +1 more

5 terms

Director Stock Option financial

"Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price": "56.0900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"1/12th of the total number of shares of common stock subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CGON director Victor Edward Tong Jr. report in this Form 4?

He reported receiving a grant of stock options for 9,354 shares of CG Oncology common stock. The options are compensation-related, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the CGON stock options granted to the director?

The options have an exercise price of $56.09 per share. This means he can buy up to 9,354 CG Oncology common shares at $56.09, regardless of the market price when he chooses to exercise, once the options have vested.

How do the CGON director stock options vest for this Form 4 grant?

The options vest in 12 equal monthly installments after June 4, 2026. If CG Oncology’s next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested options fully vest on that meeting date, subject to continued service.

When do the CG Oncology (CGON) director stock options expire?

The options expire on June 3, 2036. After this expiration date, any unexercised portion of the 9,354-share option grant can no longer be exercised, so the director must exercise vested options before that date to acquire the underlying shares.

Is this CGON Form 4 transaction a market buy or sell of shares?

No, this Form 4 reports a grant of stock options as compensation, coded as an acquisition (A). It does not reflect an open-market purchase or sale of CG Oncology common stock, but rather the award of a right to buy shares later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tong Victor Edward Jr

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$56.09	06/04/2026		A		9,354		(1)	06/03/2036	Common Stock	9,354	$0	9,354	D

Explanation of Responses:

1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Victor Edward Tong, Jr.	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)